Study S001879

A Randomized, Double-blind, Placebo-controlled Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Dosing of XW003 Injection in Chinese Adolescents With Obesity

ClinicalTrials.gov record

Registration

Registration: NCT07143227
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: DOUBLE
Status: COMPLETED
Enrollment: 48
Start: 2025-08-25
Primary completion: 2026-04-18
Lead sponsor: Hangzhou Sciwind Biosciences Co., Ltd.
Conditions: Obese Adolescents; Obesity
Interventions: DRUG:XW003 injection; DRUG:placebo with matching volume
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Number and severity of adverse events [week 20]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.